# Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

> **NCT05564338** · PHASE3 · WITHDRAWN · sponsor: **BeiGene**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sitravatinib
- **DRUG:** Tislelizumab
- **DRUG:** sitravatinib-matching placebo
- **DRUG:** tislelizumab-matching placebo

## Key facts

- **NCT ID:** NCT05564338
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06-30
- **Primary completion:** 2027-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study has voluntarily discontinued due to a change in the company-level development strategy and is not because of any safety concern or the request from any health authority worldwide.
- **Last updated:** 2023-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05564338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05564338, "Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05564338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*